2026-04-17T15:26:20Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/194452024-09-27T08:14:26Zcom_20.500.12105_19604com_20.500.12105_2051col_20.500.12105_19605

00925njm 22002777a 4500 dc Muñoz-Hernando, María author Nogales, Paula author Fernández-Barahona, Irene author Ruiz-Cabello, Jesús author Bentzon, Jacob F author Herranz, Fernando author 2024-03-28 Atherosclerosis, a leading cause of cardiovascular diseases requires approaches to enhance disease monitoring and treatment. Nanoparticles offer promising potential in this area by being customisable to target components or molecular processes within plaques, while carrying diagnostic and therapeutic agents. However, the number of biomarkers available to target this disease is limited. This study investigated the use of sphingomyelin-based nanomicelles triggered by sphingomyelinase (SMase) in atherosclerotic plaques. Accumulation of iron oxide-based nanomicelles in the plaque was demonstrated by fluorescence, MR imaging and electron microscopy. These findings demonstrate the possibility of utilising SMase as a mechanism to retain nanoprobes within plaques, thus opening up possibilities for future therapeutic interventions. Nanoscale. 2024 Mar 28;16(13):6477-6487. http://hdl.handle.net/20.500.12105/19445 38426659 10.1039/d3nr06507c 2040-3372 Nanoscale Sphingomyelinase-responsive nanomicelles for targeting atherosclerosis.